25
Views
38
CrossRef citations to date
0
Altmetric
Original Article

Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer

, , , , , , & show all
Pages 513-517 | Published online: 11 Jun 2009

References

  • Huggins C., Hodges C. V. Studies on prostate cancer. I. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297
  • Scher H. I., Curley T., Yeh S., et al. Therapeutic alternatives for hormone‐refractory prostate cancer. Semin Urol 1992; 10: 55–64
  • Hanks G. E., Myers C. E., Scardino P. T. Cancer of the prostate. Cancer: Principles and Practice of Oncology4th ed, V. T. Devita, S. Hollman, S. A. Rosenberg. Lippincott, Philadelphia 1993
  • Oesterling J. E., Martin S. K., Bergstralh E. J., et al. The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57–60
  • Pantelides M. L., Bowman S. P., George N. J. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol 1992; 70: 299–303
  • Oesterling J. E. Using PSA to eliminate the staging radionuclide bone scan: Significant economic implications. Urol Clin North Am 1993; 20: 705–711
  • Piatt J. F., Bree R. L., Schwab R. E. The accuracy of CT in the staging of carcinoma of the prostate. Am J Roentgenol 1987; 149: 315–318
  • Bluestein D. L., Bostwick D. G., Bergstralh E. J., et al. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994; 151: 1315–1320
  • Narayan P., Foumier G., Gajendran V., et al. Utility of preoperative serum prostate‐specific antigen concentration and biospy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 1994; 44: 519–524
  • Sanders H., Smith E., Woodward M., et al. The use of PSA to predict bone metastases in recurrence after definitive local therapy for prostate cancer. Proc Am Urol Assoc 1995; 153: 238A, (abstract)
  • Luke M. C., Coffey D. S. Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl 1994; 15: 41–51
  • Gulfo J. Clinical utility of monoclonal antibodies in prostate cancer. Prostate Cancer, N. A. Dawson, N. J. Vogelzang. Wiley‐Liss, New York 1994

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.